In-spite of the fact that aprotinin has been administered for more than a decade to cardiac surgery patients, it's safety is still controversial. Several studies have reported an increase risk for postoperative MI, CVA and renal failure after it's usage. Thus, its usage is not a standard of care, and depends on the surgeon decision (13).